Home » Stocks » ARTL

Artelo Biosciences, Inc. (ARTL)

Stock Price: $1.13 USD -0.01 (-0.88%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $1.11 -0.02 (-1.77%) May 13, 5:08 PM
Market Cap 26.37M
Revenue (ttm) n/a
Net Income (ttm) -5.28M
Shares Out 23.13M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.13
Previous Close $1.14
Change ($) -0.01
Change (%) -0.88%
Day's Open 1.14
Day's Range 1.08 - 1.22
Day's Volume 737,979
52-Week Range 0.45 - 3.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK

1 month ago - GlobeNewsWire

Initial safety data expected from CAReS Study before end of 2021

1 month ago - GlobeNewsWire

Detection of elevated FABP5 associated with additional tumor types suggests  the target for ART26.12 may be more broadly relevant in cancer therapy

1 month ago - GlobeNewsWire

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-si...

2 months ago - GlobeNewsWire

LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-sig...

2 months ago - GlobeNewsWire

LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathwa...

2 months ago - GlobeNewsWire

Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile Research demonstrates co-administration of CBD and TMP could confer ART12.11 wi...

2 months ago - GlobeNewsWire

Artelo Biosciences (ARTL) stock is soaring higher on Friday after Ladenburg analyst Michael Higgins initiated coverage of the company. The post ARTL Stock Alert: The Big Reason Biopharma Artelo Bioscien...

3 months ago - InvestorPlace

LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathway...

3 months ago - GlobeNewsWire

LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical m...

3 months ago - GlobeNewsWire

LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathway...

3 months ago - GlobeNewsWire

Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK

3 months ago - GlobeNewsWire

LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, ...

4 months ago - GlobeNewsWire

Expanding the patent estate for the lead clinical program to treat cancer anorexia Expanding the patent estate for the lead clinical program to treat cancer anorexia

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endoge...

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (NASDAQ:  ARTL ), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endoge...

5 months ago - GlobeNewsWire

Mitacs Accelerate grant expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders Mitacs Accelerate grant expected to fund 50% of research costs evaluatin...

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenou...

6 months ago - GlobeNewsWire

Reports positive preclinical data in animal models Reports positive preclinical data in animal models

6 months ago - GlobeNewsWire

LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to m...

6 months ago - GlobeNewsWire

LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to m...

7 months ago - GlobeNewsWire

Barry J. A. Laird, M.D. of the University of Edinburgh’s Institute of Genetics and Molecular Medicine Appointed Coordinating Investigator Barry J. A. Laird, M.D. of the University of Edinburgh’s Institu...

7 months ago - GlobeNewsWire

LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid sy...

8 months ago - GlobeNewsWire

LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid sy...

8 months ago - GlobeNewsWire

LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the e...

9 months ago - GlobeNewsWire

Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Through 2038 Claims to Improve Drug-Like Properties of CBD Receive Intellectual Property Protection Through 2038

1 year ago - GlobeNewsWire

FABP5 platform under exclusive license to Artelo Biosciences

1 year ago - GlobeNewsWire

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prosta... [Read more...]

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
ARTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ARTL stock is "Buy" and the 12-month stock price forecast is 6.00.

Price Target
$6.00
Analyst Consensus: Buy